RecruitingType 2 Diabetes

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

Eligible age

18–75 yrs

Accepts

All genders

Locations

14 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.

Sponsor: Eli Lilly and Company

You may qualify if…

✓ Have type 2 diabetes
✓ Have HbA1c ≥7.5% to ≤10.5% at screening
✓ Have a body mass index (BMI) of ≥27 kilograms per square meter (kg/m2) at screening
✓ Have had a stable body weight for the three months prior to screening
✓ On stable treatment dose of one of the following incretins for at least three months prior to screening:
✓ Injectable semaglutide (1 and 2 milligram (mg))
✓ Injectable tirzepatide (5, 7.5, 10, 12.5 and 15 mg)

You may not qualify if…

✕ Have type 1 diabetes, latent autoimmune diabetes, or history of ketoacidosis or hyperosmolar coma
✕ Have a prior or planned surgical treatment for obesity
✕ Have any of the following cardiovascular conditions within three months prior to screening:
✕ acute myocardial infarction
✕ cerebrovascular accident (stroke)
✕ unstable angina, or
✕ hospitalization due to congestive heart failure
✕ Have used insulin to control blood glucose within the past year (short-term use allowed)